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Particulate matter with an aerodynamic diameter equal or less than 2.5 micrometers (PM2.5) is associated with the development of
chronic obstructive pulmonary disease (COPD). The mechanisms by which PM2.5 accelerates disease progression in COPD are
poorly understood. In this study, we aimed to investigate the effect of PM2.5 on lung injury in rats with hallmark features of
COPD. Cardinal features of human COPD were induced in a rat model by repeated cigarette smoke inhalation and bacterial
infection for 8 weeks. Then, from week 9 to week 16, some of these rats with COPD were subjected to real-time concentrated
atmospheric PM2.5. Lung function, pathology, inflammatory cytokines, oxidative stress, and mucus and collagen production
were measured. As expected, the COPD rats had developed emphysema, inflammation, and deterioration in lung function.
PM2.5 exposure resulted in greater lung function decline and histopathological changes, as reflected by increased Mucin (MUC)
5ac, MUC5b, Collagen I, Collagen III, and the profibrotic cytokine α-smooth muscle-actin (SMA), transforming growth factor-
(TGF-) β1 in lung tissues. PM2.5 also aggravated inflammation, increasing neutrophils and eosinophils in bronchoalveolar
lavage fluid (BALF) and cytokines including Interleukin- (IL-) 1β, granulocyte-macrophage colony-stimulating factor (GM-
CSF), and IL-4. The likely mechanism is through oxidative stress as antioxidants levels were decreased, whereas oxidants were
increased, indicating a detrimental shift in the oxidant-antioxidant balance. Altogether, these results suggest that PM2.5
exposure could promote the development of COPD by impairing lung function and exacerbating pulmonary injury, and the
potential mechanisms are related to inflammatory response and oxidative stress.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is an inter-
national health problem with a rising prevalence and mortal-
ity and is estimated to be the third commonest cause of death
and the fifth leading cause of disability by 2020 [1, 2]. It is
characterized by persistent airflow limitation and chronic
airway inflammation typically caused and worsened by inha-
lation of noxious gases or particles [3]. Among the major
causes of COPD, the role of cigarette smoking is widely rec-
ognized. However, there is current evidence that a substantial
proportion of COPD cases are never smokers, especially
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among women and residents of developing countries [4–6].
According to Global Burden of Disease (GBD) study, 19.3%
of disability-adjusted life-years (DALYs) in COPD were
attributable to particulate matter (PM) exposure [7].
Numerous studies have indicated the association between
increased hospitalization, morbidity, and mortality of
COPD [8, 9], as well as aggravated respiratory function
and symptoms [10–12], and the short-term exposure to
ambient particulate air pollution including PM2.5. Ambi-
ent PM2.5 has been recognized as a major detrimental risk
factor for the development, progression, and exacerbation
of COPD.
However, our understanding of PM2.5 for the develop-
ment of COPD is still incomplete and only a few studies have
described the related mechanisms in greater details. PM2.5 is
a complex mixture of solid and liquid elements suspended in
the atmosphere, being generated from industry, coal com-
bustion, biomass fuel for cooking, and traffic pollution [13].
Its toxicity is determined by size, components, origin, and
ability to produce reactive oxygen. PM2.5 has small diameters
but large surface areas and therefore capable of carrying sev-
eral various toxic components including water-soluble ions,
transition metals, reactive gases, and polycyclic aromatic
hydrocarbons (PAHs). Due to its small size and easy transpor-
tation, PM2.5 can be inhaled deep into human airway and
deposited in lung tissues, especially alveolar regions, causing
local damage in the lungs [14]. There have been evidences that
PM2.5 has a harmful impact on lung function and alveolar
structure, and related mechanisms are focused on inflamma-
tory response, oxidative stress, immune disorders, and genetic
alterations [15–18]. In our previous studies, short-term expo-
sure of healthy rats to high-concentration PM2.5 led to a burst
of inflammation and oxidative stress in the lungs, as well as the
ciliary dysfunction in the upper airway.
It is well known that in COPD progressive airflow limita-
tion generally results from two major pathological processes,
small airway remodeling and narrowing resulting from loss
of alveolar attachments as a result of emphysema [19]. Air-
way wall thickening is caused by epithelial cell hyperplasia,
goblet cell metaplasia, and peribronchial fibrosis and is char-
acteristic of the pathology seen in the lungs of COPD patients
[20]. Longstanding inflammation is widely considered to
play a critical role in airway remodeling [21]. Mucus hyperse-
cretion may contribute to airway occlusion as mucus
occupies the airway lumen and tends to be retained because
of ciliary dysfunction [22], while several matrix metallopro-
teinases (MMPs) that degrade extracellular matrix (ECM)
are actively involved in the destruction of lung parenchyma
that leads to emphysema [23]. Degradation of ECM results
in both the liberation of matikines and latent ECM-bound
growth factors such as transforming growth factor- (TGF-)
β, resulting in lung fibrosis [24, 25].
Here, based on the successful replication of COPD rat
model, we used a whole-body PM2.5 exposure system to
explore the impact of exposure to PM2.5 on lung injury of
rats with preexisting COPD. Changes in lung function, pul-
monary histopathology, inflammatory cytokines, oxidative
stress, mucus secretion, proteinases/antiproteinases, and the
level of airway remodeling were assessed.
2. Material and Methods
2.1. Animals. Twenty-eight male Sprague-Dawley (SD) rats
(200 ± 20 g) were obtained from the Experimental Animal
Center of Shandong Province (SCXK (Lu) 20140007, Jinan,
China). All rats were fed a normal diet and housed in cages
without beddings but under standard conditions of humidity
(50 ± 10%), temperature (25 ± 2°C), and light (12 h light/12 h
dark cycle).
2.2. COPD Rat Model Establishment and Whole-Body PM2.5
Exposure. These 28 rats were randomly divided into control,
PM2.5, COPD, and PM2.5+COPD groups (7 rats per group).
The COPD rat model was prepared by using repeated ciga-
rette smoke inhalation and bacterial infection as described
previously [26]. Briefly, after equilibrating for 7 days, rats in
the COPD and PM2.5+COPD groups were exposed to ciga-
rette smoke (Hongqiqu® Filter Cigarette, Henan Tobacco
Industry, Zhengzhou, China; each cigarette contained
1.0mg nicotine, 11mg CO, and 10mg tar oil) in a self-
made exposure chamber (length: 1500 cm, width: 800 cm,
and height: 2500 cm), 30 minutes each time (smoke concen-
tration: 3000 ± 500 ppm), twice daily, with 3-hour smoke-
free intervals, 6 days per week. Additionally, Klebsiella pneu-
monia suspension (strain ID: 46114, National Center for Med-
ical Culture Collection, Beijing, China; 0.1mL, 6 × 108 colony
forming units/mL) was slowly dropped into two nasal cavities
of rats, once every 5 days, continuously for 8 weeks. The suc-
cessful establishment of the COPD rat model was decided by
decreased pulmonary function and pathological changes in
lung tissues such as pulmonary and airway inflammation,
alveolar wall thickening, alveolar cavity enlargement.
Then, in the following 8 weeks, rats in the control and
COPD groups were exposed to filtered air
(PM2:5 concentration < 10 μg/m3), while rats in the PM2.5
and PM2.5+COPD groups were exposed to concentrated
PM2.5 atmosphere in the whole-body exposure chamber
(1.2m3). The exposure protocol was 4 hours per day (8:00
am~12:00 am), 6 days per week from 30 November 2018 to
24 January 2019. All rats were anaesthetized with 3% pentobar-
bital sodium (0.25mL/100g body weight) within 24h of the last
PM2.5 exposure for collection of blood, BALF, and lung tissues
(see the flow chart of the experiment design in Figure 1).
2.3. The Parameters Monitored in Exposure Equipment. The
concentrated PM2.5 was generated using a PM2.5 concentra-
tion enrichment system (Beijing Huironghe Technology Co.,
Ltd, Beijing, China) located at the new campus of Henan
University of Chinese Medicine Zhengzhou, China, sur-
rounded by a complex of residences, schools, traffic, and
many small-scale factories. This system could make PM2.5
6~10-fold concentrated compared with the ambient.
The real-time concentrations of PM2.5 in the chamber
were monitored using a PM2.5 concentration monitor (TSI
instrument, MN, USA), and the distribution of particle size
was measured by an Aerodynamic Particle Size Analyzer
(TSI instrument, MN, USA). Humidities and temperatures
were also monitored continuously to keep a standard condi-
tion of humidity (40~60%) and temperature (21~27°C) in the
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chamber. During the exposure period, we collected PM2.5 on
the polypropylene filter (aperture: 0.8μm, Beijing, China)
that is placed at the outlet of the chamber, and then, PM2.5
were extracted for component analysis. Briefly, all filters were
cut into small pieces and put in a 50mL centrifuge tube. After
ultrasonic washing and shaking for three times repeatedly,
the extracts were passed sequentially through eight pieces of
sterile gauzes and dried by lyophilization [27]. Then, 1mg
of the PM2.5 powder was used for component analysis. Ions
were analyzed by Ion Chromatography (IC) using Thermo
Fisher Scientific Dionex ICS-2100. Microelements were ana-
lyzed by Inductively Coupled Plasma Mass Spectrometry
(ICP-MS) using Thermo Fisher Scientific iCAPQ; PAHs
were analyzed by Gas Chromatography and Mass Spectra
(GC-MS) using Thermo Fisher Scientific Trace ISQ.
2.4. Lung Histology. After 10% formalin fixing and paraffin
embedding, the lung tissue samples were sectioned into
4μm thick slides and stained with hematoxylin and eosin
(HE) for histology and morphometric analysis with an
LEICA-DM6000B microscope.
Total lung injury score (LIS) was defined by the average
score of alveolar, bronchial, and vascular injury, character-
ized by inflammatory infiltration, alveolar wall rupture and
fusion, based on Smith’s: 0 = no detectable injury, 1 = less
than 25% injury, 2 = 25%~50% injury, 3 = 50%~75% injury,
and 4=more than 75% injury [28]. Then, quantification of
emphysematous lesions was determined by mean linear
intercepts (MLI) and mean alveolar area (MAA) according
to Koike’s [29]. Briefly, theMLI was obtained from the results
of total length (L) of each line of grid divided by the number
of alveolar intercepts (NAI). The MAA was defined as the
results of airspace surfaces (S) divided by the number of alve-
oli (NA). All analyses were conducted by two trained pathol-
ogists blinded to the study protocol.
2.5. Pulmonary Function. Tidal volume (TV), peak expira-
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Figure 1: Experimental protocol. SD rats were divided into control, PM2.5, COPD, and PM2.5+COPD groups. During weeks 0~8, for the
COPD and PM2.5+COPD groups, the COPD rat model was prepared by using repeated cigarette smoke inhalation and bacterial
infection. During weeks 8~16, rats in the PM2.5 and PM2.5+COPD groups were exposed to concentrated PM2.5 atmosphere in the
whole-body exposure chamber, 4 hours per day. Rats in the control group were exposed to filtered air all the time. At weeks 0, 4, 8, 12,
and 16, the noninvasive lung function (TV, PEF, and EF50) were measured. All rats were sacrificed within 24 h of the last PM2.5
exposure. And lung function, pulmonary histopathology, inflammatory cytokines, oxidative stress, mucus secretion, and
proteinases/antiproteinases were detected. Control: healthy rats; PM2.5: particulate matter 2.5 treatment alone rats; COPD: chronic
obstructive pulmonary disease rats; PM2.5+COPD: COPD rats exposed to prolonged PM2.5 for 8 weeks. TV: tidal volume; PEF: peak
expiratory flow; EF50: expiratory flow 50%.
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(EF50) were measured by an unrestrained whole body ple-
thysmograph (Buxco Inc., Wilmington, NC, USA) at weeks
0, 4, 8, 12, and 16. By the end of week 16, forced expiratory
vital capacity (FVC), forced expiratory volume in 0.3 s
(FEV0.3), and FEV0.3/FVC were measured after rats were
anaesthetized and inserted with a tracheal cannula by using
a computer-controlled pulmonary function test system
(Buxco Inc., DSI, St. Paul, MN, USA).
2.6. Collection of Bronchoalveolar Lavage Fluid (BALF) and
Cell Classification. After rats were sacrificed, the left lungs
were lavaged twice with 3mL of phosphate-buffered solution
(PBS) through tracheal intubation and up to 50% recovery
was obtained. 10μL of the recovered lavage fluid was used
for total cell counts using cell-count boards. The BALF
supernatant and sediment were then obtained by centrifuga-
tion at 1200 rpm for 10 minutes in 4°C. Numbers of eosino-
phils, neutrophils, and macrophages were determined in a
total of 200 cells using HE staining under microscope. All
analyses were conducted by two trained pathologists blinded
to the study protocol.
2.7. Enzyme-Linked Immunosorbent Assay. Levels of Inter-
leukin- (IL-) 1β, IL-4, granulocyte-macrophage colony-
stimulating factor (GM-CSF), matrix metalloproteinase 9
(MMP-9), and matrix metalloproteinase 12 (MMP-12) and
tissue inhibitor of metalloproteinases (TIMP-1) were mea-
sured using individual ELISA kits (Boster/Elabscience Tech-
nology Co., Wuhan, China) under the manufacturer’s
instructions.
2.8. Western Blotting. Total protein was extracted from lung
tissues using cold RIPA buffer containing protease and phos-
phatase inhibitors (Solarbio, Beijing, China). The protein
expressions of nuclear factor erythroid 2-related factor 2
(Nrf-2) and heme oxygenase-1 (HO-1) in lung tissues were
measured using Western blot. Anti-Nrf-2 Ab (1 : 1000, Lian-
keBio, Hangzhou, China), anti-HO-1 Ab (1 : 500, GeneTex,
USA), and anti-GAPDH Ab (1 : 5000, GeneTex, USA) were
used. ChemiDoc™ MP (Bio-Rad, Hercules, CA, USA) imag-
ing system was used to record signals. ImageJ was used to
quantify the intensity of the protein band, which was normal-
ized to GAPDH in the analysis.
2.9. Immunohistochemistry. After heat fixed, deparaffinized,
and rehydrated through graded alcohols to distilled water,
lung tissue paraffin sections (4μm) were blocked with 5%
bull serum albumin and incubated with the primary antibod-
ies against Mucin (MUC) 5ac, MUC5b, transforming growth
factor- (TGF-) β1, α-smooth muscle-actin (SMA) (Bioss,
Beijing, China), and Collagen I, Collagen III (Proteintech,
Wuhan, China) overnight at 4°C. Subsequently, the sections
were incubated with goat anti-rabbit IgG at 37°C for 30
minutes and counterstained by hematoxylin according to
the manufacturers’ instructions (Boster, Wuhan, China).
Finally, images were captured and analyzed using the
Image-ProPlus 6.0 software (Media Cybernetics, MD, USA).
2.10. Measurement of MDA and T-SOD in Serum and BALF.
Activity of malondialdehyde (MDA) and total superoxide
dismutase (T-SOD) in serum and BALF was measured by
hydroxylamine and thiobarbituric acid methods, respec-
tively, according to the manufacturer’s protocol (Nanjing
Jiancheng Co., Jiangsu, China).
2.11. Statistical Analysis. All statistical analyses were per-
formed by SPSS software, version 23.0, for Windows (IBM,
Armonk, NY, USA). Data were presented as mean ±
standard deviation (SD). One-way analysis of variance
(ANOVA) was used to determine statistical differences
between the groups. A p value of <0.05 was considered statis-
tically significant.
3. Results
3.1. PM2.5 Concentration. The maximum and minimum
concentrations of PM2.5 in the chamber were
2227.64μg/m3 and 205.12μg/m3, respectively. The average
concentration for 8 weeks of exposure was 739.97μg/m3.
Figure S1 (Supplementary Materials) shows the daily
atmospheric concentration of PM2.5 after being
concentrated during the exposure period.
3.2. PM2.5 Exposure Aggravated Lung Histological Injury in
COPD Rats. As shown in Figure 2, the structure of pulmo-
nary alveoli and airway was fully intact in control rats. In
contrast, rats in the COPD group showed alterations in both
alveolar and tracheal areas, including inflammatory cell infil-
tration, alveolar wall thickening, alveolar cavity enlargement,
and small conducting airway thickening. In comparison,
PM2.5 alone rats were less severe. PM2.5 exposure further
increased infiltration of inflammatory cells and thickening
of alveolar and airway wall in COPD rats, but without ampli-
fying alveolar cavity.
We then used LIS, MLI, and MAN for quantification of
this lung injury and found both LIS and MLI increased,
whereas MAN decreased in all 3 treated groups in compari-
son to the control. Meanwhile, a further increase in LIS and
MLI and a further decrease in MANwere observed in the rats
with combined exposure.
3.3. PM2.5 Exposure Promoted Airway Remodeling in COPD
Rats. Airway remodeling occurs in COPD and is positively
correlated to COPD severity. The major contributor to this
is increased ECM proteins [30]. TGF-β1 is a major profi-
brotic cytokine which induces ECM deposition [25]. As
shown in Figure 3, a significant upregulation in the pro-
tein expression of TGF-β1 was observed in lung tissues
of PM2.5 and COPD rats and further elevated in com-
bined treated rats. Similarly, Collagen I and Collagen III,
other predominant ECM proteins [31], were markedly
increased in these treatment groups, and the combined
treatment was higher than PM2.5 or COPD alone. Airway
smooth muscle (ASM) hypertrophy is another hallmark of
airway remodeling [25]. We next detected the lung protein
expression of ASM marker α-SMA and found that it sig-
nificantly increased in all 3 treatment groups, with the
highest in the PM2.5+COPD group.
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3.4. PM2.5 Exposure Impaired Pulmonary Function in COPD
Rats. Pulmonary function is an important indicator for respi-
ratory disease development. As shown in Figure 4, all 3
treated groups had significantly decreased TV, PEF, and
EF50 in comparison to control. In COPD rats, these three
noninvasive parameters declined with time and were stable
from week 8 onwards. In rats with combined exposure, a fur-
ther decrease in TV, PEF, and EF50 occurred after PM2.5
exposure. Similarly, the invasive lung function parameters
FVC, FEV0.3, and FEV0.3/FVC were also reduced in COPD

















































































Figure 2: The effect of PM2.5 on lung histological injury in rats with COPD. (a) Lung tissue HE staining of different groups of rats. (i)
Control, an intact structure of pulmonary alveoli and airway (magnification, ×100); (ii) PM2.5, mild infiltration of inflammatory cells and
thickening of airway wall (magnification, ×100); (iii) COPD, alveolar cavity enlargement and vascular wall thickening (magnification,
×100); (iv) PM2.5+COPD, chronic obstructive bronchiolitis with thickening of the airway wall and infiltration with inflammatory cells
(magnification, ×100); (v) COPD, airway wall thickening and inflammatory cell infiltration (magnification, ×200); (vi) PM2.5+COPD,
increased thickening of airway wall and infiltration of inflammatory cells compared to COPD (magnification, ×200). (b–d) Quantitative
analysis of lung injury, that is, the level of (b) LIS, (c) MLI, and (d) MAN of the lungs in each group. LIS: lung injury scores; MLI: mean
linear intercept; MAN: mean alveolar number. The data are expressed as the means ± SD (n = 6~7). ∗∗p < 0:01, ∗p < 0:05.
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3.5. PM2.5 Exposure Enhanced Inflammatory Response in
COPD Rats. COPD is associated with chronic lung inflamma-
tion. As shown in Figure 5(a), the total amount of cells in BALF
and the percentage of eosinophils, neutrophils, and macro-
phages in the PM2.5, COPD, and PM2.5+COPD groups were
higher than those in the control group. And compared to the
COPD group, the percent of neutrophils and eosinophils in
the PM2.5+COPD group was significantly increased.
As shown in Figure 5(b), some inflammatory cytokines
were detected. Levels of IL-1β, GM-CSF, and IL-4 were
markedly upregulated in the three treatment groups com-
pared to the control rats. PM2.5 exposure, moreover, mark-
edly enhanced these three proinflammatory cytokines in
COPD rats.
3.6. PM2.5 Exposure Worsened Oxidative Stress in COPD
Rats. Oxidative stress is a critical driving mechanism in
COPD [32]. To investigate the effect of PM2.5 on oxida-
tive stress in COPD rats, the expressions of antioxidants
and oxidants in serum and BALF were measured. As
shown in Figures 6(a), T-SOD activity was markedly
decreased in both serum and BALF of PM2.5, COPD, and
PM2.5+COPD rats, and this decrease in the PM2.5+COPD
group is greater than that in the COPD group. On the other
hand, MDA, a biomarker of lipid peroxidation, was markedly
increased by all treatments and further increased in the PM2.5
+COPD group.
Nrf-2 is a redox-sensitive transcription factor inducing
antioxidant expression and negatively associated with the















































































Figure 3: The effect of PM2.5 on airway remodeling in rats with COPD. (a) Immunohistochemical staining of TGF-β, α-SMA, Collagen I,
and Collagen III of lung sections in each group (magnification, ×200). (b) Quantitative analysis of TGF-β, α-SMA, Collagen I, and
Collagen III using Image-ProPlus 6.0 software. TGF-β1: transforming growth factor-beta 1; α-SMA: α-smooth muscle-actin; IOD: integral
optical density. The data are expressed as the means ± SD (n = 6). ∗∗p < 0:01, ∗p < 0:05.
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severity of COPD [33, 34]. We evaluated the protein levels of
Nrf2 and its major downstream factor HO-1 in the lungs of
rats by Western blot. As shown in Figure 6(b), PM2.5 expo-
sure clearly decreased the levels of Nrf2 and HO-1 protein
in COPD rats.
3.7. PM2.5 Exposure Increased Mucus Secretion in COPD Rat.
In COPD, mucus hypersecretion is not only one of the most
frequent symptoms but also a critical pathological factor. As
shown in Figure 7, MUC5ac and MUC5b, the predominant
mucins that contribute to the viscoelastic properties of
mucus [22], both were increased in the PM2.5 and COPD
rats and further increased in the combined treatment groups.
This data indicated that PM2.5 exposure enhanced mucus
hypersecretion in COPD rats.
3.8. PM2.5 Exposure Elevated Protease-Antiprotease
Imbalance in COPD Rats. Another plausible mechanism for
the development of emphysema is the overproduction of
proteases such as MMPs relative to their inhibitors TIMPs
[23]. In this study, we measured MMP-9, MMP-12, and
TIMP-1. As shown in Figure 8, the PM2.5 and COPD groups
had elevated MMP-9 and MMP-12 and decreased in TIMP-
1. Moreover, MMP-9 and MMP-12 in combined treatment
were further increased and TIMP-1 further decreased relative
to the individual treatment groups.
4. Discussion
Our results demonstrated that PM2.5 exposure significantly
impaired lung function and histology in COPD rats. More-
over, inflammation, oxidative stress, mucus hypersecretion,
and protease-antiprotease imbalance were worsened in
COPD rats after PM2.5 exposure. This is the first study to
evaluate the effect of PM2.5 on preexisting COPD in multiple
aspects using a whole-body PM2.5 exposure system, which
mimic the clinical situation in many countries with episodic
increases in PM2.5 pollution.
WHO data shows that around 91% of the world’s popu-
lation live in places where air quality levels exceed WHO
guideline limits, with developing low-income and middle-









































































































































Figure 4: The effect of PM2.5 on pulmonary function in rats with COPD. (a) The change of noninvasive lung function parameters TV, PEF,
and EF50 of rats in each group from week 0 to week 16, as well as at week 16. (b) The change of invasive lung function parameters FVC,
FEV0.3, and FEV0.3/FVC of rats in each group at week 16. TV: tidal volume; PEF: peak expiratory flow; EF50: expiratory flow 50%; FVC:
forced vital capacity; FEV0.3: forced expiratory volume at 0.3 s; FEV0.3/FVC: forced expiratory volume at 0.3 s/forced vital capacity. The

































































































































Figure 5: The effect of PM2.5 on inflammatory response in rats with COPD. (a) The total cell count and percentage of neutrophils,
eosinophils, and macrophages in the BALF of rats in each group. (b) Level of IL-1β and IL-4 in the lung and GM-CSF in the BALF of rats
in each group. IL-1β: Interleukin-1β; IL-4: Interleukin-4; GM-CSF: granulocyte-macrophage colony-stimulating factor. The data are



























































































































Figure 6: The effect of PM2.5 on oxidative stress in rats with COPD. (a) The levels of MDA and T-SOD in the serum and BALF of rats in each
group. (b) Protein expression levels of Nrf-2 and HO-1 in the lung measured by Western blotting. MDA: malondialdehyde; T-SOD: total
superoxide dismutase; Nrf-2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1. The data are expressed as the means ±
SD (n = 3~7). ∗∗p < 0:01, ∗p < 0:05.
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indoors and outdoors [35]. To decrease ambient PM2.5
levels, governments worldwide have introduced air quality
guidelines. According to WHO ambient air quality guide-
lines, the suggested PM2.5 concentration limit is 25μg/m3
for the 24-hour mean, and it is 75μg/m3 in China. However,
levels are frequently exceeded. In China, rapid economic
development and urbanization have a real cost to the envi-
ronment. Air pollution has posed the fourth highest risk fac-
tor contributing to deaths and DALYs in China [36]. PM2.5
levels in 56.2% of 338 Chinese major cities in 2018 exceeded
the concentration limit of China [37]. Located in central
China, Zhengzhou has a temperate continental monsoon cli-
mate with cold-dry winter and ranked in the top ten of the
most air polluted cities in China [38]. In winter, notably, its
PM2.5 emission usually showed an upward trend owing to
the coal combustion for space heating purposes during its
4-month long heating periods [39, 40]. For this reason, a
period from November 30, 2018, to January 24, 2019, was
chosen for PM2.5 exposure in this study. The data showed
that the average daily PM2.5 concentration was







































Figure 7: The effect of PM2.5 exposure on mucus hypersecretion in rats with COPD. (a) Immunohistochemical staining of MUC5ac and
MUC5b in the lung sections of each group (magnification, ×200). (b) Quantitative analysis of MUC5ac and MUC5b using Image-
ProPlus 6.0 software. MUC5ac: Mucin5ac; MUC5b: Mucin5b; IOD: integral optical density. The data are expressed as the means ±

























































Figure 8: The effect of PM2.5 on protease-antiprotease imbalance in rats with COPD. Level of MMP-9, MMP-12, and TIMP-1 in the BALF of
rats in each group. MMP-9: matrix mettaloproteinase-9; TIMP-1: tissue inhibitors of metalloproteases-1. The data are expressed as the
means ± SD (n = 7). ∗∗p < 0:01, ∗p < 0:05.
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739.97μg/m3 in the chamber, which was far more than the
limit of bothWHO and China, the concentration enrichment
equipment realizing a short-term PM2.5 infection. In addi-
tion, this level was close to that in our previous study
(626.9μg/m3), which was also performed in a winter heating
period from 15 December to 28 December 2017. So it is rea-
sonable to suppose that the average PM2.5 concentration
monitored in the same place and time period is repeatable
by using this equipment.
Our COPD rat model is generated by a combination of
cigarette smoke exposure and repeated bacterial infections
and recapitulates many features of human COPD. Impor-
tantly, in this model, the impaired pulmonary function and
pathological changes in the lungs were irreversible over the
32-week observation period [26]. In the present study, we
examined the rats’ pulmonary function and lung tissue
pathology to verify the replication of the COPD model. The
lung function (TV, PEF, and EF50) in the COPD group
declined with time from week 1 to week 8, being stable over
the 16-week experiment period. By the end of week 16, both
noninvasive (TV, PEF, and EF50) and invasive (FVC,
FEV0.3, and FEV0.3/FVC) lung function parameters in the
COPD group were significantly lower in comparison to those
in the control, indicating an irreversible airflow limitation in
COPD rats. The pathological results suggested that rats in the
COPD group developed more lung tissue injury than con-
trols, including inflammatory cell infiltration, alveolar wall
thickening, alveolar cavity enlargement, and small conduct-
ing airway thickening.
Based on the successful establishment of the COPD rat
model, we used a whole-body PM2.5 exposure system to rep-
licate COPD rats exposed to concentrated PM2.5 atmo-
sphere. In the chamber, more than 90% particles were less
than 2.5μm (see Table S1 in Supplementary Materials).
After 8 weeks of exposure, an exacerbating effect of PM2.5
exposure on functional and histological lung damage was
readily observed in COPD rats. These findings highlighted
the potential use of such method to contribute to animal
studies on the chronic hazards of air pollutants to human
health. And we hypothesize that this exposure method is
more realistic than other previous methods, such as
intratracheal instillation in the form of PM2.5 suspension
liquid with a stable PM2.5 concentration or ultrasonic
nebulization in the form of PM2.5 aerosols [17, 18, 40, 41].
However, it is regrettable that the levels of other gas
pollutants including ozone, SO2, and NO2, which have also
been demonstrated to contribute to lung injury and COPD
development, were ignored to be measured in this study
[42]. But according to Chu et al. and Zhou et al.’s studies,
in which the same PM2.5 exposure equipment was used,
concentrations of CO, O3, NO2, and SO2 were monitored
both in filtered air and concentrated PM2.5 air chambers
and no significant differences were found during the
exposure [43, 44].
PM2.5 consists of a complex mixture of toxic constitu-
ents including free radicals, transition metals, organic chemi-
cals, and microbial components that play critical roles in
biological pathogenicity [14]. Metals attached to the surface
of PM2.5 trigger a series of catalytic reactions and free radical
formation, leading to lipid peroxidation in the cell membrane
and inflammation [45]. PM2.5-bound PAHs can cause oxi-
dative damage by activating cytochrome P450 family
enzymes, which may upregulate unstable intermediary
metabolites and impair human bronchial epithelium [46].
In the present study with repeated measurements, abundant
NO3-, NH4+, SO42-, Fe, Pb, and K, as well as kinds of PAHs,
were detected in these collected PM2.5 samples (see Table S2
in Supplementary Materials). The particles breach of
mucociliary barrier, reach distal airways, and deposit in
alveolar regions [47], thereby eliciting oxidative stress with
broken DNA strands, protein carbonylation, lipid
peroxidation, and impaired antioxidant system [48].
COPD sufferers may be particularly susceptible to the
adverse effects of particle pollutants due to the preexisting
impaired lung function, chronic airway inflammation, and
ineffective clearance ability [49]. After PM2.5 exposure, an
obvious augment in oxidant-antioxidant imbalance was
observed in COPD rats, as reflected by increased MDA level
while decreased T-SOD activation in the PM2.5+COPD
group compared to those in the COPD group. Besides, most
antioxidants are regulated by the transcription factor Nrf2,
which is negatively associated with the severity of COPD.
In this context, the expression of Nrf2 protein, as well as its
downstream factor HO-1, showed a downward trend in the
lungs of PM2.5-exposed COPD rats.
This PM2.5-increased oxidative stress may stimulate air-
way epithelial cells and surface macrophages to release more
inflammatory mediators such as IL-1β, GM-CSF, and IL-4,
resulting in an enhancement in chronic inflammation in
COPD rats exposed to PM2.5 inhalation. These cytokines,
furthermore, enhanced inflammatory cell infiltration and
mucus hypersecretion, thereby aggravating airway stenosis
and remolding, as exhibited in the lung histopathology exam-
ination. PM2.5 exposure also elevated expressions of mucins
such as MUC5ac and MUC5b and collagen-related bio-
markers Collagen I and Collagen III in lung tissues of COPD
rats. Additionally, the development of airway remolding and
emphysema in COPD is highly linked to overwhelmed prote-
ase activity such as MMPs that participate in the degradation
of elastic fibers and extracellular matrix [23]. We further
observed an increment in MMPs (MMP-9 and 12) and dec-
rement in their inhibitor TIMP-1 in COPD rats after
PM2.5 exposure, which may result from excessive oxidants
and inflammatory cells induced by PM2.5.
These results demonstrated that PM2.5 aggravates
COPD through multiple ways, including oxidative stress, air-
way inflammation, mucus hypersecretion, proteases/antipro-
tease imbalance, and airway remodeling. We speculated that
oxidative stress may play a central role. Once deposited on
the surface of pulmonary bronchioli and alveoli, PM2.5
elicits oxidative stress, which further triggers a range of path-
ogenic processes starting with activation of proteases, then
enhancing bronchial inflammation, goblet cell hyperplasia,
and mucus hypersecretion, afterward increasing small airway
fibrosis and collagen deposition, thereby resulting in elevated
chronic inflammation and lung emphysema that demon-
strate the development of COPD. However, further studies
are required to clarify such hypothesis.
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5. Conclusions
Altogether, our data suggest that PM2.5 exposure markedly
increased oxidative stress, inflammation, proteases, hyperse-
cretion of mucus and collagen, and airflow obstruction in rats
with preexisting COPD. This study highlights the need to
incorporate questions about exposure to pollution in patients
who have COPD and importantly will allow new therapeutics
to be evaluated in these models.
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